Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

2022163 citationsJournal Articlegold Open Access

Authors

Jicheng Lv · Chinese Academy of Medical Sciences & Peking Union Medical College

Lijun Liu · Chinese Academy of Medical Sciences & Peking Union Medical College

Chuan‐Ming Hao · Fudan University

Guisen Li · University of Electronic Science and Technology of China

Ping Fu · Sichuan University

Guangqun Xing · Qingdao University

Hongguang Zheng

Abstract

Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.

Topics & Keywords

Renal Diseases and Glomerulopathies Platelet Disorders and Treatments Complement system in diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Kidney International Reports

Volume 8, Issue 3, pp. 499-506

DOI: 10.1016/j.ekir.2022.12.014

Field-Weighted Citation Impact: 20.20